Trial of ganglioside GM1 in acute stroke
Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 1988-09, Vol.51 (9), p.1213-1214 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1214 |
|---|---|
| container_issue | 9 |
| container_start_page | 1213 |
| container_title | Journal of neurology, neurosurgery and psychiatry |
| container_volume | 51 |
| creator | Hoffbrand, B I Bingley, P J Oppenheimer, S M Sheldon, C D |
| description | Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment of acute stroke in the dose and route of administration used. |
| doi_str_mv | 10.1136/jnnp.51.9.1213 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1033029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3984082881</sourcerecordid><originalsourceid>FETCH-LOGICAL-b514t-f6eef7939e101e713b309a3cb907b8718e5f01ee3f46cb64d9589a34a94877803</originalsourceid><addsrcrecordid>eNqFkUtv1DAUha2Kqgyl2-6QIoEQXST4jhM_NpXaUR9IBTalqrq5cjLO4GnGHuwE0X-P0xmNgA3eeHE-n3uPDyHHQAsAxj8unVsXFRSqgCmwPTKBksucMXr_gkwonU5zRiv6kryKcUnHI9UBOWCUc1mqCflwG6zuMt9mC-0WnfXRzk129Rky6zLdDL3JYh_8o3lN9lvdRXO0vQ_Jt8uL29l1fvP16tPs7CavKyj7vOXGtEIxZYCCEcBqRpVmTa2oqKUAaao2CYa1JW9qXs5VJZNealVKISRlh-R047se6pWZN8b1QXe4DnalwxN6bfFvxdnvuPA_EWgKPVXJ4P3WIPgfg4k9rmxsTNdpZ_wQUUguuChZAt_-Ay79EFwKhyBE8gJWiUQVG6oJPsZg2t0qQHFsAMcGsAJUODaQHrz5M8AO33550t9tdR0b3bVBu8bGHZYGM_UcI99gNvbm107W4RG5YKLCL3czPGcPd5fwIHAce7Lh69Xyfyv-BmizqPY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1773021357</pqid></control><display><type>article</type><title>Trial of ganglioside GM1 in acute stroke</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Hoffbrand, B I ; Bingley, P J ; Oppenheimer, S M ; Sheldon, C D</creator><creatorcontrib>Hoffbrand, B I ; Bingley, P J ; Oppenheimer, S M ; Sheldon, C D</creatorcontrib><description>Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment of acute stroke in the dose and route of administration used.</description><identifier>ISSN: 0022-3050</identifier><identifier>EISSN: 1468-330X</identifier><identifier>DOI: 10.1136/jnnp.51.9.1213</identifier><identifier>PMID: 3066849</identifier><identifier>CODEN: JNNPAU</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cardiovascular system ; Cerebral Infarction - therapy ; Clinical Trials as Topic ; Dose-Response Relationship, Drug ; Double-Blind Method ; G(M1) Ganglioside - administration & dosage ; Humans ; Injections, Intramuscular ; Medical sciences ; Middle Aged ; Miscellaneous ; Pharmacology. Drug treatments ; Random Allocation</subject><ispartof>Journal of neurology, neurosurgery and psychiatry, 1988-09, Vol.51 (9), p.1213-1214</ispartof><rights>1989 INIST-CNRS</rights><rights>Copyright BMJ Publishing Group LTD Sep 1988</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b514t-f6eef7939e101e713b309a3cb907b8718e5f01ee3f46cb64d9589a34a94877803</citedby><cites>FETCH-LOGICAL-b514t-f6eef7939e101e713b309a3cb907b8718e5f01ee3f46cb64d9589a34a94877803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1033029/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1033029/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7303929$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3066849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoffbrand, B I</creatorcontrib><creatorcontrib>Bingley, P J</creatorcontrib><creatorcontrib>Oppenheimer, S M</creatorcontrib><creatorcontrib>Sheldon, C D</creatorcontrib><title>Trial of ganglioside GM1 in acute stroke</title><title>Journal of neurology, neurosurgery and psychiatry</title><addtitle>J Neurol Neurosurg Psychiatry</addtitle><description>Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment of acute stroke in the dose and route of administration used.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Cerebral Infarction - therapy</subject><subject>Clinical Trials as Topic</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>G(M1) Ganglioside - administration & dosage</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Pharmacology. Drug treatments</subject><subject>Random Allocation</subject><issn>0022-3050</issn><issn>1468-330X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkUtv1DAUha2Kqgyl2-6QIoEQXST4jhM_NpXaUR9IBTalqrq5cjLO4GnGHuwE0X-P0xmNgA3eeHE-n3uPDyHHQAsAxj8unVsXFRSqgCmwPTKBksucMXr_gkwonU5zRiv6kryKcUnHI9UBOWCUc1mqCflwG6zuMt9mC-0WnfXRzk129Rky6zLdDL3JYh_8o3lN9lvdRXO0vQ_Jt8uL29l1fvP16tPs7CavKyj7vOXGtEIxZYCCEcBqRpVmTa2oqKUAaao2CYa1JW9qXs5VJZNealVKISRlh-R047se6pWZN8b1QXe4DnalwxN6bfFvxdnvuPA_EWgKPVXJ4P3WIPgfg4k9rmxsTNdpZ_wQUUguuChZAt_-Ay79EFwKhyBE8gJWiUQVG6oJPsZg2t0qQHFsAMcGsAJUODaQHrz5M8AO33550t9tdR0b3bVBu8bGHZYGM_UcI99gNvbm107W4RG5YKLCL3czPGcPd5fwIHAce7Lh69Xyfyv-BmizqPY</recordid><startdate>19880901</startdate><enddate>19880901</enddate><creator>Hoffbrand, B I</creator><creator>Bingley, P J</creator><creator>Oppenheimer, S M</creator><creator>Sheldon, C D</creator><general>BMJ Publishing Group Ltd</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19880901</creationdate><title>Trial of ganglioside GM1 in acute stroke</title><author>Hoffbrand, B I ; Bingley, P J ; Oppenheimer, S M ; Sheldon, C D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b514t-f6eef7939e101e713b309a3cb907b8718e5f01ee3f46cb64d9589a34a94877803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Cerebral Infarction - therapy</topic><topic>Clinical Trials as Topic</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>G(M1) Ganglioside - administration & dosage</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Pharmacology. Drug treatments</topic><topic>Random Allocation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoffbrand, B I</creatorcontrib><creatorcontrib>Bingley, P J</creatorcontrib><creatorcontrib>Oppenheimer, S M</creatorcontrib><creatorcontrib>Sheldon, C D</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoffbrand, B I</au><au>Bingley, P J</au><au>Oppenheimer, S M</au><au>Sheldon, C D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trial of ganglioside GM1 in acute stroke</atitle><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><date>1988-09-01</date><risdate>1988</risdate><volume>51</volume><issue>9</issue><spage>1213</spage><epage>1214</epage><pages>1213-1214</pages><issn>0022-3050</issn><eissn>1468-330X</eissn><coden>JNNPAU</coden><abstract>Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment of acute stroke in the dose and route of administration used.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><pmid>3066849</pmid><doi>10.1136/jnnp.51.9.1213</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3050 |
| ispartof | Journal of neurology, neurosurgery and psychiatry, 1988-09, Vol.51 (9), p.1213-1214 |
| issn | 0022-3050 1468-330X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1033029 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Cardiovascular system Cerebral Infarction - therapy Clinical Trials as Topic Dose-Response Relationship, Drug Double-Blind Method G(M1) Ganglioside - administration & dosage Humans Injections, Intramuscular Medical sciences Middle Aged Miscellaneous Pharmacology. Drug treatments Random Allocation |
| title | Trial of ganglioside GM1 in acute stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A49%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trial%20of%20ganglioside%20GM1%20in%20acute%20stroke&rft.jtitle=Journal%20of%20neurology,%20neurosurgery%20and%20psychiatry&rft.au=Hoffbrand,%20B%20I&rft.date=1988-09-01&rft.volume=51&rft.issue=9&rft.spage=1213&rft.epage=1214&rft.pages=1213-1214&rft.issn=0022-3050&rft.eissn=1468-330X&rft.coden=JNNPAU&rft_id=info:doi/10.1136/jnnp.51.9.1213&rft_dat=%3Cproquest_pubme%3E3984082881%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1773021357&rft_id=info:pmid/3066849&rfr_iscdi=true |